University of Crete (UOC)
Η κλινική σημασία της χορήγησης συνδυασμών αμινογλυκοσιδών με βήτα λακταμικά αντιβιοτικά σε νοσοκομειακούς ασθενείς με σοβαρές λοιμώξεις
Abstract
dc:descriptionBackground: Pseudomonas aeruginosa bacteremia represents a severe infection. The use of antibiotic combinations represents a common therapeutic approach for decades. Several recent original papers and systematic reviews questioned the benefit of using beta-lactams in combination with other antimicrobials for various serious bacterial infections. It is not clear whether beta-lactam monotherapy leads to similar rates of treatment success compared to combinations of beta-lactams with aminoglycosides or quinolones for the treatment of Pseudomonas aeruginosa bacteremia.Methods: Retrospective cohort study from 3 tertiary hospitals (2 in Greece and 1 in Italy). Pseudomonas aeruginosa isolates were susceptible to a beta-lactam and an aminoglycoside or a quinolone. Patients received appropriate therapy for at least 48 hours. Primary outcome of interest was treatment success in patients with definitive beta-lactam combination therapy compared to monotherapy. Secondary outcomes were treatment success keeping the same empirical and definitive regimen, all-cause mortality, mortality attributed to infection, and toxicity.Results: Out of 92 Pseudomonas aeruginosa bacteremias that were retrieved in the databases of the hospitals, there were 54 episodes fullfiling the inclusion criteria for the primary outcome (20 received monotherapy). Treatment success was higher with combination therapy (85%) compared to beta-lactam monotherapy (65%), however not statistically significantly [Odds ratio (OR) 3.1; 95% Confidence Interval (CI) 0.69–14.7, p = 0.1]. Very long (>2 months) hospitalisation before bacteremia was the only factor independently associated with treatment success (OR 0.73; 95% CI 0.01–0.95, p = 0.046), however this result entailed few episodes. All-cause mortality did not differ significantly between combination therapy [6/31 (19%)] and monotherapy [8/19 (42%)], p = 0.11. Only Charlson comorbidity index was associated with excess all-cause mortality. Mortality due to infection was 3/31 (10%) in patients that received combination therapy compared to 5/19 (26%) in the monotherapy group. Only very long duration of hospitalisation was associated with mortality attributed to infection.Conclusion: Our study, in accordance with previous studies, indicates that the choice between appropriate definitive monotherapy with a beta lactam may not alter treatment success and other outcomes significantly compared to appropriate definitive combination therapy with a beta-lactam plus an aminoglycoside or a quinolone in patients with Pseudomonas aeruginosa bacteremia. However, our study does not have the statistical power to identify small differences regarding in outcomew between treatment groups. Recent guidelines on the management of patients with sepsis suggest broad spectrum empirical antimicrobial coverage. However, at the same time they suggest narrow definitive therapy (de-escalation) based on susceptibility testing results, in agreement with our results. A large multicentre randomized controlled trial can offer good quality evidence and further insights regarding the optimal therapy for Pseudomonas aeruginosa bacteremia.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2016
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Bliziotis, Ioannis
- Μπληζιώτης, Ιωάννης
Subjects
dc:subject × 17- Ψευδομονάδα
- Σήψη
- Συνδυασμοί φαρμάκων
- Μονοθεραπεία
- ΒΗΤΑ-ΛΑΚΤΑΜΙΚΑ ΑΝΤΙΒΙΟΤΙΚΑ
- Αμινογλυκοσίδες
- ΑΝΤΙΒΙΟΤΙΚΑ-ΚΙΝΟΛΟΝΕΣ
- Sepsis
- Pseudomonas aeruginosa
- Monotherapy
- B-lactam antibiotics
- Aminoglycoside antibiotics
- ANTIBIOTICS-QUINOLONE
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/37839